A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
NCT ID: NCT06465914
Last Updated: 2024-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
9000 participants
INTERVENTIONAL
2024-07-11
2030-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will inoculate the 9-valent HPV vaccine or a placebo according to the 0, 2, 6 month immunization program.
Visit the clinic on the 8th and 31st day after each dose of vaccination for the collection of safety information, keeping a diary of their symptoms and medications.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine
Participants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha). Follow-up for the study encompassed Month 7 through Month 72.
9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
Placebo
Participants in this arm would receive Placebo. Follow-up for the study encompassed Month 7 through Month 72.
Placebo
Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
Placebo
Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects fully understands the study procedures, understands the risks and benefits associated with participating in the study, and voluntarily signs the informed consent;
3. Subjects are able to read, understand and fill in the research application forms such as diary CARDS and contact CARDS, and promise to participate in regular follow-up according to the study requirements;
4. Heterosexual men subjects must have exclusively female sexual partners and no more than 5 before enrollment;
5. MSM subject must have had sex with men within the past year (either insertive or receptive anal intercourse); and the cumulative number of sexual partners (including male and female sexual partners) does not exceed 5 before enrollment;
6. Subjects agree to provide effective contact information that can be used for communication with the researchers during the study;
7. Subjects consent to external anogenital lesion inspection and sample collection (including but not limited to wet swab collection and necessary biopsy) during the study period;
8. Subjects agree to take effective contraceptive measures from the first dose to 1 month after the last dose \[male effective contraception including abstinence, male condom, vasectomy, etc.; female valid contraception including the pill (excluding emergency contraception), injection or embedded contraception, sustained-release topical contraceptives, hormonal patch, intrauterine devices (IUD), sterilization, diaphragm, cervical caps, etc.; safe period contraception, extracorporeal ejaculation, and emergency contraception are unacceptable contraception.\]
Exclusion Criteria
2. \* Higher blood pressure on the day of the first vaccination (systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg);
3. \* Sexual activity (including anal, vaginal/genital contact of the same or opposite sex) within 48 hours prior to the sampling visit; Self-shave hair from genital area within 24 hours prior to the genital examination visit (and/or using any post-shaving lotions or lubricants);
4. Have been or planned to be vaccinated with commercially available HPV vaccine; Have participated in or plan to participate in other HPV vaccine clinical trials;
5. Previous positive HPV test results (including types not included in the investigational vaccine) or related cytological abnormalities；
6. Previous or current HPV-related genital warts, penile/perianal/perineal intraepithelial neoplasia, penile/perianal/perineal cancer, anal intraepithelial neoplasia, or anal cancer;
7. Significant clinical evidence of external genital lesions and anal diseases (only MSM) suggesting the HPV infection during the external anogenital inspection before the first vaccination;
8. \* Acute illness or acute episode of chronic disease, or use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) within 3 days prior to vaccination;
9. \* Received inactivated/recombinant/nucleic acid vaccine (non-attenuated vaccine) within 7 days prior to recruitment, or attenuated vaccine within 14 days prior to enrollment;
10. \* Received any immune globulin or blood derived products within 3 months prior to enrollment, or plan to use any between the first vaccination and 1 month after full immunization;
11. \* Received immunosuppressive therapy within 1 month prior to vaccination, such as immunosuppressive doses of glucocorticoids (dose reference: equivalent to prednisone 20mg/day for more than 7 days), or monoclonal antibodies, thymosin, interferon, etc., or plan to receive such treatment during the first dose until 1 month after full immunization, but topical administration (such as ointment, eye drops, inhalants or nasal sprays) is allowed;
12. Other investigational or unregistered products (drug or vaccine) that have been used within 3 months prior to the first dose or are planned to be used during the study period;
13. Present or have a history of convulsions (except febrile convulsions in childhood (0-14 years)), epilepsy, other serious neurological diseases (such as transverse myelitis, Guillain-Barre syndrome, demyelinating diseases, etc.);
14. Present or have a history of mental illness or the family history;
15. There are contraindications to intramuscular injection, such as having been diagnosed with thrombocytopenia, any coagulation dysfunction, or being treated with anticoagulants;
16. Any condition resulting in asplenia or functional asplenia；
17. A history of severe allergic reactions requiring medical intervention (such as anaphylactic shock, anaphylactic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis (Arthus reaction), etc.); A history of severe adverse reactions to previous vaccination or a history of severe allergies (e.g. mouth and throat swelling, dyspnea, hypotension or shock, severe urticaria, etc.) to any vaccine component (histidine, sodium chloride, polysorbate 80, aluminum phosphate adjuvant and water for injection) ;
18. Subjects have been diagnosed with congenital or acquired immunodeficiency disease, such as: AIDS, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease or other immune disorders;
19. Currently have a serious infectious disease such as active tuberculosis, active viral hepatitis or acquired immunodeficiency syndrome (HIV infection);
20. Diagnosed with a serious congenital malformation or chronic disease that may interfere with the conduct or completion of the study, such as Down syndrome, heart disease, liver disease, kidney disease, diabetes with complications, or malignant tumors;
21. A history of drug abuse prior to enrolling, or a history of drug or alcohol abuse or dependence within the last year;
22. Subjects plan to permanently relocate from the region before the completion of the study or leave the region for a long period of time during the scheduled visit (affecting the scheduled visit time);
23. Investigators consider that the subjects have any condition that may interfere with the evaluation of the objectives of the study, or that participation in the study does not guarantee the maximum benefit of the subjects.
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Bovax Biotechnology Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lidong Gao, Master
Role: PRINCIPAL_INVESTIGATOR
Hunan Provincial Center for Disease Control and Prevention
Long Sui, Doctor
Role: PRINCIPAL_INVESTIGATOR
Obstetrics & Gynecology Hospital of Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
Nanning, Guangxi, China
Hunan Center for Disease Control and Prevention
Changsha, Hunan, China
Shanxi Provincial Disease for Control and Prevention
Taiyuan, Shanxi, China
Sichuan Center for Disease Control and Prevention
Chengdu, Sichuan, China
Yunnan Center for Disease Control and Prevention
Kunming, Yunnan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9-HPV-3004
Identifier Type: -
Identifier Source: org_study_id